NCT01431924View on ClinicalTrials.gov

Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients

CompletedOBSERVATIONAL
Enrollment

7,779

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Asthma
Interventions
DRUG

Higher-dose inhaled corticosteroids

fluticasone propionate 110 or 220 mcg

DRUG

Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination

Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01431924 - Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients | Biotech Hunter | Biotech Hunter